Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 5 |
| List of Tables | 8 | 1 |
| List of Figures | 9 | 1 |
| Biomarkers in Drug Discovery - Introduction | 10 | 1 |
| Introduction | 10 | 1 |
| Biomarkers in Drug Discovery - Overview | 11 | 8 |
| History of Biomarkers | 11 | 2 |
| Biomarkers Cater to the Unmet Needs in Drug Discovery | 13 | 1 |
| High Attrition Rates | 14 | 1 |
| High Drug Discovery Cost | 15 | 1 |
| Time Consuming | 15 | 1 |
| Safety and Efficacy | 15 | 1 |
| Invasiveness, Selectivity and Sensitivity | 15 | 1 |
| Biomarker Discovery and the Validation Process | 16 | 1 |
| Discovery | 16 | 1 |
| Development | 17 | 1 |
| Reproduction and Assay | 17 | 1 |
| Verification | 17 | 1 |
| Assay Development | 17 | 1 |
| Preclinical and Clinical Development | 17 | 1 |
| Launch | 17 | 1 |
| Regulatory Submission and Market Planning | 17 | 2 |
| Biomarkers in Drug Discovery - Market Characterization | 19 | 6 |
| Market Size and Forecasts | 19 | 1 |
| Global Biomarkers Market Geographic Landscape | 20 | 1 |
| Introduction | 20 | 1 |
| North America | 20 | 1 |
| Europe | 20 | 1 |
| Asia | 21 | 1 |
| Row | 21 | 1 |
| Drivers and Barriers | 21 | 1 |
| Drivers for the Global Biomarkers Market | 22 | 1 |
| Time and Cost-Saving | 22 | 1 |
| Better Regulatory Norms and Validation Procedures | 22 | 1 |
| Extensive Range of Applications in Different Industrial Sectors | 22 | 1 |
| Integration of Omics Increases the Scope of Application for Biomarkers in Other Technologies | 23 | 1 |
| Advantageous Over Conventional Drug Discovery Methods | 24 | 1 |
| Barriers for the Global Biomarkers Market | 24 | 1 |
| Lack of Awareness about Intelligent and Novel Technological Advances | 24 | 1 |
| Complex Biomarker-based Techniques May Lead to False Positive Results Misleading the Clinical Trials | 24 | 1 |
| Funding Organizations Require Strong Clinical Data and Validation | 24 | 1 |
| Cumbersome and Lengthy Development | 24 | 1 |
| Biomarkers in Drug Discovery - Time Trends | 25 | 5 |
| Historic Trend | 25 | 1 |
| Predictions Based on Biomarkers | 25 | 1 |
| Validation Versus Qualification | 25 | 1 |
| Lack of Synergy between Mechanism and Pattern | 25 | 1 |
| Regulatory Approval of Biomarkers | 26 | 1 |
| Difference in Regulation of Single Biomarkers and Panel of Biomarkers | 26 | 1 |
| Measures of Success | 26 | 1 |
| Future Trend Growing Demand for Personalized Medicine | 27 | 1 |
| Companion Diagnostics Market | 27 | 1 |
| Drivers and Barriers for Companion Diagnostics Market | 28 | 1 |
| Regulations of Companion Diagnostics EU | 28 | 1 |
| Regulations of Companion Diagnostics US | 29 | 1 |
| Biomarkers in Drug Discovery - Technologies Used for Biomarker Discovery | 30 | 6 |
| Role of Imaging as a Predictive Biomarker | 30 | 2 |
| Biomarker Discovery Using Proteomics via Mass Spectrometry | 32 | 2 |
| High-Throughput Proteome Screening for Biomarker Detection | 34 | 2 |
| Biomarkers in Drug Discovery - How Biomarker Development Relates to Drug Discovery | 36 | 13 |
| Application of Biomarkers in Drug Discovery | 36 | 2 |
| Lead Identification and Optimization | 38 | 1 |
| Potential Role of Biomarkers in Lead Identification and Optimization | 39 | 1 |
| Target Validation | 39 | 1 |
| Toxicological Assay (Preclinical and Clinical) | 39 | 1 |
| Mechanism of Action | 40 | 1 |
| Monitor Therapy and Dose Response | 40 | 1 |
| Stratify Patient Population | 40 | 1 |
| Filing and Post-Marketing Surveillance | 41 | 1 |
| Benefits of Biomarker Utilization | 41 | 1 |
| Disease Understanding | 41 | 1 |
| Project Prioritization through Early Attrition | 41 | 1 |
| Streamlining Clinical Trials | 41 | 1 |
| Reducing Cost of Drug Development | 42 | 1 |
| Expediting Drug Development | 42 | 1 |
| Avoiding Adverse Drug Reactions and Rationalizing Dosing Regimen | 42 | 1 |
| Drug Repositioning | 42 | 1 |
| Challenges in Biomarker Utilization | 42 | 1 |
| Variability | 42 | 1 |
| Validity | 43 | 1 |
| Measurement Errors | 43 | 1 |
| Bias | 43 | 1 |
| Confounding | 43 | 1 |
| Cost | 43 | 1 |
| Acceptability | 43 | 1 |
| Biomarker Classification | 44 | 1 |
| Biomarker Categories | 45 | 1 |
| Types of Biomarkers | 45 | 1 |
| Type 0 Markers | 45 | 1 |
| Type I Marker | 46 | 1 |
| Type II Biomarker | 46 | 1 |
| Reasons for Surrogate Endpoint Failure | 47 | 2 |
| Biomarkers in Drug Discovery - Integration of Biomarkers in Different Phases of Drug Development | 49 | 4 |
| Discovery | 50 | 1 |
| Predictive Safety Biomarkers | 50 | 1 |
| Mechanism of Action Markers | 50 | 1 |
| Preclinical Development | 50 | 1 |
| Prognostic and Epidemiological Biomarkers | 50 | 1 |
| Diagnostic Biomarkers | 51 | 1 |
| Clinical Development | 52 | 1 |
| Disease Progression Markers or Response to Therapy Markers | 52 | 1 |
| Surrogate Biomarkers | 52 | 1 |
| Biomarkers in Drug Discovery - Case Study | 53 | 6 |
| Role of HER2 Gene in Herceptin Development for Breast Cancer | 53 | 1 |
| Activation of Antibody-Dependent Cellular Cytotoxicity | 53 | 1 |
| Prevention of the Formation of p95HER2 | 53 | 1 |
| Inhibition of HER2-activated Cell Proliferation | 54 | 1 |
| Inhibition of HER2-regulated Angiogenesis | 54 | 1 |
| Herceptin Side Effects | 55 | 2 |
| Role of BCR-ABL Fusion Protein in Development of Gleevec for Chronic Myelogenous Leukemia | 57 | 2 |
| Biomarkers in Drug Discovery - Regulatory Trends | 59 | 7 |
| Regulatory Landscape | 59 | 1 |
| Investigative/Exploratory Biomarker | 59 | 1 |
| Probable Valid Biomarker | 59 | 1 |
| Known Valid Biomarker | 59 | 1 |
| Letter Of Intent to Propose Biomarker Qualification | 59 | 1 |
| Administrative Structure | 59 | 1 |
| Biomarker Qualification Overview | 59 | 1 |
| Overall Summaries of the Following (as appropriate) | 59 | 1 |
| Questions for the FDA | 59 | 1 |
| Structure of Biomarker Qualification Briefing Document | 60 | 2 |
| Validated Biomarker | 62 | 3 |
| Regulatory Acceptance of Valid Biomarkers | 65 | 1 |
| Regulatory Guidance from the FDA, EMA and MHLW | 65 | 1 |
| Biomarkers in Drug Discovery - Promising Biomarkers | 66 | 9 |
| Biomarkers for Alzheimer s Disease | 66 | 1 |
| Imaging Biomarkers | 66 | 1 |
| Magnetic Resonance Imaging | 66 | 1 |
| Positron Emission Tomography Scans | 66 | 1 |
| Fluid Biomarkers | 67 | 1 |
| Cerebrospinal Fluid Biomarkers | 67 | 1 |
| Plasma Biomarkers | 67 | 1 |
| Biomarkers for Cancer | 67 | 2 |
| Insulin-like Growth Factor 1 and 2 | 69 | 1 |
| OVA1 | 69 | 1 |
| Risk of Ovarian Malignancy Algorithm | 69 | 1 |
| Serum Markers | 69 | 1 |
| Micro RNAs | 69 | 1 |
| Biomarkers for Multiple Sclerosis | 70 | 1 |
| Serum Marker: Brain-Derived Neurotrophic Factor | 70 | 1 |
| Cerebrospinal Fluid Markers | 70 | 1 |
| Imaging Marker | 71 | 1 |
| Biomarkers for Rheumatoid Arthritis | 71 | 1 |
| Micro RNAs | 71 | 1 |
| Autoantibodies | 72 | 1 |
| Rheumatoid Factor | 72 | 1 |
| Antibodies against Cyclic Citrullinated Peptide | 72 | 1 |
| Inflammatory Markers | 72 | 1 |
| Erythrocyte Sedimentation Rate | 72 | 1 |
| C-Reactive Protein | 72 | 1 |
| Biomarkers for Hepatitis C | 73 | 1 |
| Serum Markers | 73 | 1 |
| Imaging Markers | 73 | 1 |
| Non-Structural 5A Protein | 74 | 1 |
| Micro RNA-22 | 74 | 1 |
| Biomarkers in Drug Discovery - Strategic Consolidations | 75 | 6 |
| M&A Deals | 75 | 1 |
| Micromedic Buys 33% Stake in BioMarCare for $1m | 75 | 1 |
| ValiRx Plc Acquires Pharmatest s Biomarkers Business Unit | 75 | 1 |
| David H. Murdock Research Institute Acquires the Immune Tolerance Institute | 76 | 1 |
| Health Diagnostic Laboratory Acquires Harris Scientific | 76 | 1 |
| Myriad Genetics Acquires Rules-based Medicine | 76 | 1 |
| Licensing Agreements | 77 | 1 |
| SomaLogic Enters into Licensing Agreement with AmberGen | 77 | 1 |
| Advion BioServices Enters into Licensing Agreement with SISCAPA Assay Services | 77 | 1 |
| AVEO Pharmaceuticals Enters into Licensing Agreement with Centocor Ortho Biotech | 78 | 1 |
| KineMed Extends Licensing Agreement with Bristol-Myers Squibb | 78 | 1 |
| Partnership Deals | 79 | 1 |
| KineMed Enters Multi-year Agreement with GlaxoSmithKline to Develop Kinetic Biomarkers | 80 | 1 |
| Affymetrix and Massachusetts General Hospital Seal Deal to Develop Cancer Biomarker Diagnostics | 80 | 1 |
| Genedata and Roche Extend Collaboration of Biomarker Discovery | 80 | 1 |
| Isogen Life Science Enters into Co-Marketing Agreement with Axela for Biomarker Analysis Platforms | 80 | 1 |
| Biomarkers in Drug Discovery - Appendix | 81 | 7 |
| Market Definitions | 81 | 1 |
| Abbreviations | 81 | 2 |
| Bibliography | 83 | 3 |
| Research Methodology | 86 | 2 |
| Coverage | 86 | 1 |
| Secondary Research | 86 | 1 |
| Primary Research | 86 | 1 |
| Expert Panel Validation | 87 | 1 |
| Contact Us | 87 | 1 |
| Disclaimer | 87 | 1 |